(Q33439701)

26 July 2017

Post-licensure safety surveillance for Prevenar 13® in France (English)

1 reference

26 July 2017

M-S Agier

1

1 reference

26 July 2017

S Marchand

2

1 reference

26 July 2017

N Paret

3

1 reference

26 July 2017

S Gautier

4

1 reference

26 July 2017

A-P Jonville-Béra

5

1 reference

26 July 2017

language of work or name

French

0 references

publication date

24 February 2017

1 reference

26 July 2017

Archives de Pediatrie

1 reference

26 July 2017

24

1 reference

26 July 2017

5

1 reference

26 July 2017

439-444

1 reference

Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study

26 July 2017

1 reference

12 December 2020

[Post licensure safety surveillance for Prevenar]

1 reference

12 December 2020

Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and pasteur-mérieux sérums et vaccins

1 reference

12 December 2020

Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying

1 reference

12 December 2020

Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden

1 reference

12 December 2020

Hypotonic-hyporesponsive episodes following pertussis vaccination: a cause for concern?

1 reference

12 December 2020

Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children

1 reference

12 December 2020

Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: a meta-analysis

1 reference

12 December 2020

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway

1 reference

12 December 2020

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination

1 reference

12 December 2020

Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate v

1 reference

12 December 2020

Sudden unexpected death in infants under 3 months of age and vaccination status- -a case-control study

1 reference

12 December 2020

Randomised controlled trial: Prophylactic paracetamol at the time of infant vaccination reduces the risk of fever but also reduces antibody response

1 reference

12 December 2020

Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010

1 reference

12 December 2020

Collapse reactions after whole cell pertussis vaccination

1 reference

12 December 2020

10.1016/J.ARCPED.2017.01.018

Identifiers

DOI

1 reference

26 July 2017

0 references

1 reference